Published in
Lippincott, Williams & Wilkins, AIDS, 5(26), p. 567-575, 2012
DOI: 10.1097/qad.0b013e32834f337c
Links
Tools
Renal function in patients with HIV starting therapy with tenofovir and either efavirenz, lopinavir or atazanavir
Journal article published in 2012 by
Jim Young 
,
Juliane Schäfer,
Christoph A. Fux,
Hansjakob Furrer,
Enos Bernasconi,
Pietro Vernazza,
Alexandra Calmy,
Matthias Cavassini,
Rainer Weber,
Manuel Battegay,
Heiner C. Bucher,
Swiss Hiv Cohort Study
,
Juliane Schäfer,
Christoph A. Fux,
Hansjakob Furrer,
Enos Bernasconi,
Pietro Vernazza,
Alexandra Calmy,
Matthias Cavassini,
Rainer Weber,
Manuel Battegay,
Heiner C. Bucher,
Swiss Hiv Cohort Study
This paper is made freely available by the publisher.
Full text: Download
Published version:
archiving forbidden
Data provided by 
Abstract
Tenofovir is associated with reduced renal function, but it is not clear whether there is a greater decline in renal function when tenofovir is co-administered with a boosted protease inhibitor rather than with a nonnucleoside reverse transcriptase inhibitor (NNRTI).